300006 莱美药业
已收盘 12-23 15:00:00
资讯
新帖
简况
莱美药业(300006)12月10日股东户数2.84万户，较上期增加1.25%
证券之星 · 12-19
莱美药业(300006)12月10日股东户数2.84万户，较上期增加1.25%
莱美药业连亏近6年亟待脱困 中恒集团“A卖A”拟11亿保本撤退
长江商报 · 12-19
莱美药业连亏近6年亟待脱困 中恒集团“A卖A”拟11亿保本撤退
中恒集团(600252.SH)控股子公司莱美药业参加第十批全国药品集中采购拟中选
智通财经 · 12-13
中恒集团(600252.SH)控股子公司莱美药业参加第十批全国药品集中采购拟中选
中恒集团最新公告：控股子公司莱美药业产品尼莫地平注射液拟中选第十批全国药品集中采购
证券之星 · 12-13
中恒集团最新公告：控股子公司莱美药业产品尼莫地平注射液拟中选第十批全国药品集中采购
莱美药业(300006.SZ)：尼莫地平注射液拟中选全国药品集采
智通财经 · 12-13
莱美药业(300006.SZ)：尼莫地平注射液拟中选全国药品集采
莱美药业最新公告：公司产品尼莫地平注射液拟中选第十批全国药品集中采购
证券之星 · 12-13
莱美药业最新公告：公司产品尼莫地平注射液拟中选第十批全国药品集中采购
莱美药业：尼莫地平注射液拟中选全国药品集中采购
美港电讯 · 12-13
莱美药业：尼莫地平注射液拟中选全国药品集中采购
底价4.42元/股！莱美药业：中恒集团拟转让23.43%股份
东方财富 · 12-13
底价4.42元/股！莱美药业：中恒集团拟转让23.43%股份
中恒集团最新公告：拟以公开征集受让方方式转让莱美药业23.43%股份获广西国资委批复
证券之星 · 12-12
中恒集团最新公告：拟以公开征集受让方方式转让莱美药业23.43%股份获广西国资委批复
中恒集团(600252.SH)拟公开征集莱美药业23.43%股份受让方 转让价不低于4.42元/股
智通财经 · 12-12
中恒集团(600252.SH)拟公开征集莱美药业23.43%股份受让方 转让价不低于4.42元/股
莱美药业(300006.SZ)控股股东中恒集团拟公开征集方式协议转让23.43%股份
智通财经 · 12-12
莱美药业(300006.SZ)控股股东中恒集团拟公开征集方式协议转让23.43%股份
莱美药业：控股股东拟公开转让持有的2.47亿股
大河财立方 · 12-12
莱美药业：控股股东拟公开转让持有的2.47亿股
莱美药业最新公告：控股股东拟协议转让23.43%股份
证券之星 · 12-12
莱美药业最新公告：控股股东拟协议转让23.43%股份
中恒集团拟出让莱美药业控制权
中国经营网 · 12-07
中恒集团拟出让莱美药业控制权
莱美药业成“烫手山芋”？ 国资控股股东欲“脱手”，连亏5年靠什么翻身
市场资讯 · 12-06
莱美药业成“烫手山芋”？ 国资控股股东欲“脱手”，连亏5年靠什么翻身
莱美药业（300006）11月29日主力资金净卖出4165.12万元
证券之星 · 12-02
莱美药业（300006）11月29日主力资金净卖出4165.12万元
莱美药业(300006.SZ)：尼莫地平注射剂、奥美拉唑镁肠溶片被纳入医保目录
智通财经 · 11-29
莱美药业(300006.SZ)：尼莫地平注射剂、奥美拉唑镁肠溶片被纳入医保目录
中恒集团转让莱美药业股份 持续亏损后的战略调整？
电鳗快报 · 11-29
中恒集团转让莱美药业股份 持续亏损后的战略调整？
时隔四年半莱美药业或再度“易主” 已连续五年亏损
新京报 · 11-28
时隔四年半莱美药业或再度“易主” 已连续五年亏损
重庆A股58家上涨 莱美药业20%涨幅第一 远达环保10%涨停
上游新闻 · 11-28
重庆A股58家上涨 莱美药业20%涨幅第一 远达环保10%涨停
加载更多
公司概况
公司名称：
重庆莱美药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-10-30
主营业务：
重庆莱美药业股份有限公司的主要业务为医药制造，公司产品品种丰富，结构合理，公司主要产品为化药，涵盖特色专科类（主要包括抗肿瘤药、消化系统药、肠外营养药）、抗感染类等。公司重点品种纳米炭混悬注射液(卡纳琳)，系首款获得CFDA批准的淋巴示踪剂，卡纳琳连续四年获得“中国化学制药行业原研药,专利药优秀产品品牌”,连续两年获得“中国化学制药行业其他各科用药优秀产品品牌”,获得“制造业单项冠军产品(2019-2021年)”,“2021年中国产学研合作创新与促进奖”等多项荣誉称号。
发行价格：
16.50
{"stockData":{"symbol":"300006","market":"SZ","secType":"STK","nameCN":"莱美药业","latestPrice":4.9,"timestamp":1734937419000,"preClose":5.26,"halted":0,"volume":39581680,"delay":0,"floatShares":1056000000,"shares":1056000000,"eps":0.0182,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.36,"latestTime":"12-23 15:00:00","open":5.31,"high":5.33,"low":4.8,"amount":196000000,"amplitude":0.1008,"askPrice":4.91,"askSize":795,"bidPrice":4.9,"bidSize":3817,"shortable":0,"etf":0,"ttmEps":0.0182,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735003800000},"adr":0,"adjPreClose":5.26,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":5.79,"lowLimit":4.73,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1055911205,"pbRate":2.7,"roa":"--","roe":"--","epsLYR":-0.0085,"committee":0.119545,"marketValue":5174000000,"floatMarketCap":5174000000,"peRate":269.230758,"changeRate":-0.0684,"turnoverRate":0.0375,"status":1},"requestUrl":"/m/hq/s/300006","defaultTab":"news","newsList":[{"id":"2492614182","title":"莱美药业(300006)12月10日股东户数2.84万户，较上期增加1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492614182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492614182?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:10","pubTimestamp":1734599457,"startTime":"0","endTime":"0","summary":"证券之星消息，近日莱美药业披露，截至2024年12月10日公司股东户数为2.83万户，较11月20日增加349.0户，增幅为1.25%。在化学制药行业个股中，莱美药业股东户数低于行业平均水平，截至12月10日，化学制药行业平均股东户数为3.11万户。从股价来看，2024年11月20日至2024年12月10日，莱美药业区间涨幅为24.74%，在此期间股东户数增加349.0户，增幅为1.25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900028341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2492193983","title":"莱美药业连亏近6年亟待脱困 中恒集团“A卖A”拟11亿保本撤退","url":"https://stock-news.laohu8.com/highlight/detail?id=2492193983","media":"长江商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492193983?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:38","pubTimestamp":1734568737,"startTime":"0","endTime":"0","summary":"5年前，中恒集团大举杀入莱美药业，斥资10.83亿元通过包揽定增，取得莱美药业的控股股东之位。中恒集团谋求退出在实际控制5年后，中恒集团筹划退出莱美药业。公告称，如果本次公开征集受让方及转让股份事项顺利完成，莱美药业的控股股东及实际控制人将发生变更。2021年3月，莱美药业完成定增，中恒集团、中恒同德、广投国宏合计出资10.84亿元包揽。2019年以来，莱美药业持续亏损。2019年以来，莱美药业扣非净利润累计为亏损9.27亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219084911ab83106d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219084911ab83106d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","600252","300006","BK0077","BK0028","BK0188","BK0239","BK0070","BK0015"],"gpt_icon":0},{"id":"2491323985","title":"中恒集团(600252.SH)控股子公司莱美药业参加第十批全国药品集中采购拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2491323985","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491323985?lang=zh_cn&edition=full","pubTime":"2024-12-13 19:07","pubTimestamp":1734088067,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中恒集团(600252.SH)公告，公司控股子公司重庆莱美药业股份有限公司(简称“莱美药业”)参加了由国家组织药品联合采购办公室(简称“联采办”)组织开展的第十批全国药品集中采购投标工作。根据联采办发布的《全国药品集中采购拟中选结果公示》，莱美药业产品尼莫地平注射液拟中选本次集中采购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","300006","BK0239","600252","BK0028","BK0015","BK0188","BK0070","BK0077"],"gpt_icon":0},{"id":"2491328550","title":"中恒集团最新公告：控股子公司莱美药业产品尼莫地平注射液拟中选第十批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491328550","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491328550?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:39","pubTimestamp":1734086381,"startTime":"0","endTime":"0","summary":"中恒集团公告称，公司控股子公司莱美药业参加了第十批全国药品集中采购投标工作，产品尼莫地平注射液拟中选本次集中采购。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300036506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600252","BK0028","BK0070","BK0015","BK0188","BK0239","BK0077","BK0012","300006"],"gpt_icon":0},{"id":"2491347812","title":"莱美药业(300006.SZ)：尼莫地平注射液拟中选全国药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2491347812","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491347812?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:05","pubTimestamp":1734084313,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)公告，公司参加了由国家组织药品联合采购办公室组织开展的第十批全国药品集中采购投标工作。根据联采办发布的《全国药品集中采购拟中选结果公示》，公司产品尼莫地平注射液拟中选本次集中采购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300006","BK0239","BK0070"],"gpt_icon":0},{"id":"2491473243","title":"莱美药业最新公告：公司产品尼莫地平注射液拟中选第十批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491473243","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491473243?lang=zh_cn&edition=full","pubTime":"2024-12-13 18:00","pubTimestamp":1734084041,"startTime":"0","endTime":"0","summary":"莱美药业公告，公司参加了由国家组织药品联合采购办公室组织的第十批全国药品集中采购投标工作，产品尼莫地平注射液拟中选本次集中采购。该产品主要用于预防和治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛引起的缺血性神经损伤，拟中选价格为3.90元/瓶。本次拟中选将有利于促进该产品的销售和市场拓展，提升公司的品牌影响力，对公司的长远发展具有积极的影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300034147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2491892342","title":"莱美药业：尼莫地平注射液拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491892342","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491892342?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:55","pubTimestamp":1734083750,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2491031535","title":"底价4.42元/股！莱美药业：中恒集团拟转让23.43%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2491031535","media":"东方财富","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491031535?lang=zh_cn&edition=full","pubTime":"2024-12-13 13:16","pubTimestamp":1734066960,"startTime":"0","endTime":"0","summary":"截至目前，中恒集团直接持有莱美药业约2.47亿股股份，通过控股子企业南宁中恒同德医药产业投资基金合伙企业持有约2144.7万股，二者合计持股比例达25.46%，为公司控股股东。莱美药业提示，若本次中恒集团公开征集股份完成，公司的控股股东和实际控制人可能发生变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-13/doc-inczhxxx5947733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600252","BK0028","BK0070","BK0015","BK0188","BK0239","BK0077","BK0012","300006"],"gpt_icon":0},{"id":"2490387932","title":"中恒集团最新公告：拟以公开征集受让方方式转让莱美药业23.43%股份获广西国资委批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2490387932","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490387932?lang=zh_cn&edition=full","pubTime":"2024-12-12 23:00","pubTimestamp":1734015647,"startTime":"0","endTime":"0","summary":"中恒集团公告，公司于2024年11月27日披露了拟以公开征集受让方方式转让公司持有的莱美药业23.43%股份的提示性公告。2024年12月12日，公司收到控股股东广西投资集团有限公司通知，本次转让方案已取得广西壮族自治区人民政府国有资产监督管理委员会的批复，原则同意中恒集团公开征集其持有莱美药业247,426,064股A股股份意向受让方的事项。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200037890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0188","300006","BK0012","600252","BK0070","BK0015","BK0239"],"gpt_icon":0},{"id":"2490805959","title":"中恒集团(600252.SH)拟公开征集莱美药业23.43%股份受让方 转让价不低于4.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490805959","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490805959?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:44","pubTimestamp":1734000248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中恒集团(600252.SH)发布公告，公司拟通过公开征集受让方的方式协议转让持有的重庆莱美药业股份有限公司(简称“莱美药业”)2.47亿股无限售条件流通股A股股票，占莱美药业总股本的23.43%，转让价格不低于提示性公告日前30个交易日的每日加权平均价格的算术平均值即4.42元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","600252","BK0188","BK0070","BK0012","BK0239","BK0028","300006","BK0015"],"gpt_icon":0},{"id":"2490056048","title":"莱美药业(300006.SZ)控股股东中恒集团拟公开征集方式协议转让23.43%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2490056048","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490056048?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:41","pubTimestamp":1734000117,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)公告，公司控股股东广西梧州中恒集团股份有限公司(简称“中恒集团”)拟通过公开征集受让方的方式协议转让持有的公司2.47亿股无限售条件流通股A股股票，占公司总股本的23.43%，转让价格不低于4.42元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","600252","BK0012","BK0077","BK0015","BK0188","300006","BK0028","BK0239"],"gpt_icon":0},{"id":"2491339222","title":"莱美药业：控股股东拟公开转让持有的2.47亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491339222","media":"大河财立方","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491339222?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:31","pubTimestamp":1733999496,"startTime":"0","endTime":"0","summary":"12月12日，莱美药业公告，控股股东广西梧州中恒集团股份有限公司拟通过公开征集受让方的方式协议转让持有的公司2.47亿股无限售条件流通股A股股票，占总股本的23.43%，转让价格不低于4.42元/股。莱美药业表示，本次公开征集转让的实施可能导致公司控股股东和实际控制人发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212183751ab722c82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212183751ab722c82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600252","300006","BK0077","BK0015","BK0012","BK0028","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2490803687","title":"莱美药业最新公告：控股股东拟协议转让23.43%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2490803687","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490803687?lang=zh_cn&edition=full","pubTime":"2024-12-12 18:20","pubTimestamp":1733998821,"startTime":"0","endTime":"0","summary":"莱美药业公告，控股股东中恒集团拟通过公开征集受让方的方式协议转让持有的公司2.47亿股无限售条件流通股A股股票，占公司总股本的23.43%，转让价格不低于4.42元/股。若此次股份转让完成，公司的控股股东及实际控制人可能发生变更。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200030865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300006","BK0239"],"gpt_icon":0},{"id":"2489226742","title":"中恒集团拟出让莱美药业控制权","url":"https://stock-news.laohu8.com/highlight/detail?id=2489226742","media":"中国经营网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489226742?lang=zh_cn&edition=full","pubTime":"2024-12-07 03:40","pubTimestamp":1733514021,"startTime":"0","endTime":"0","summary":"随着协议的生效，中恒集团成为莱美药业拥有最大表决权份额的单一股东，同时莱美药业的实际控制人变更为广西国资委。此外，中恒集团承诺在协议签署生效后的一年内，通过二级市场直接购买或接受大股东转让的莱美药业股票，增持比例不少于莱美药业总股本的5%。5年累计亏损超6亿元实际上，中恒集团拟出让莱美药业控制权的背后，反映的是莱美药业业绩长期处于亏损状态的困境。莱美药业方面表示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207062935ab63b801&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207062935ab63b801&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0070","BK0012","600252","300006","BK0077","BK0028","BK0239","BK0015"],"gpt_icon":0},{"id":"2489449474","title":"莱美药业成“烫手山芋”？ 国资控股股东欲“脱手”，连亏5年靠什么翻身","url":"https://stock-news.laohu8.com/highlight/detail?id=2489449474","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489449474?lang=zh_cn&edition=full","pubTime":"2024-12-06 08:29","pubTimestamp":1733444940,"startTime":"0","endTime":"0","summary":" 近日，重庆莱美药业股份有限公司在公告中披露，公司收到控股股东广西梧州中恒集团股份有限公司的通知，后者正筹划有关公司的股份公开征集转让事宜，该事项可能导致公司的控股股东及实际控制人发生变更。 中恒集团于2020年4月成为莱美药业大股东，截至上述公告披露日，中恒集团通过直接或间接合计持有莱美药业268,873,842 股股份为控股股东，广西国资委为实际控制人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-12-06/doc-incynrnw9018449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0070","300006"],"gpt_icon":0},{"id":"2488661621","title":"莱美药业（300006）11月29日主力资金净卖出4165.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488661621","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488661621?lang=zh_cn&edition=full","pubTime":"2024-12-02 09:18","pubTimestamp":1733102318,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月29日收盘，莱美药业报收于5.11元，下跌6.07%，换手率7.16%，成交量75.62万手，成交额3.94亿元。近5日资金流向一览见下表：莱美药业融资融券信息显示，融资方面，当日融资买入3541.41万元，融资偿还2943.24万元，融资净买入598.16万元。莱美药业主营业务：医药制造。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200002041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300006","BK0070","BK0239"],"gpt_icon":0},{"id":"2487537176","title":"莱美药业(300006.SZ)：尼莫地平注射剂、奥美拉唑镁肠溶片被纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487537176","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487537176?lang=zh_cn&edition=full","pubTime":"2024-11-29 19:20","pubTimestamp":1732879254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，根据国家医疗保障局、人力资源社会保障部发布的《关于印发<国家基本医疗保险、工伤保险和生育保险药品目录(2024年)>的通知》，公司尼莫地平注射剂、奥美拉唑镁肠溶片被纳入《医保目录(2024年)》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0239","300006"],"gpt_icon":0},{"id":"2487023183","title":"中恒集团转让莱美药业股份 持续亏损后的战略调整？","url":"https://stock-news.laohu8.com/highlight/detail?id=2487023183","media":"电鳗快报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487023183?lang=zh_cn&edition=full","pubTime":"2024-11-29 13:30","pubTimestamp":1732858200,"startTime":"0","endTime":"0","summary":"11月27日，莱美药业与中恒集团同时发布公告，宣布中恒集团正在筹划有关莱美药业的股份公开征集转让事宜，这一转让可能导致公司控股股东及实际控制人发生变更。中恒集团于2020年成为莱美药业的控股股东，然而，在其后的四年多时间里，莱美药业一直未能摆脱亏损状态。中恒集团入主莱美药业，本意是将莱美药业作为其生物医药产业的重要平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129133301abe7bb3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129133301abe7bb3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300006","BK0012","BK0028","BK0077","600252","BK0188","BK0015","BK0070","BK0239"],"gpt_icon":0},{"id":"2486351962","title":"时隔四年半莱美药业或再度“易主” 已连续五年亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2486351962","media":"新京报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486351962?lang=zh_cn&edition=full","pubTime":"2024-11-28 13:22","pubTimestamp":1732771320,"startTime":"0","endTime":"0","summary":"自2019年以来，莱美药业一直处于亏损状态。控股股东正筹划转让事宜11月26日晚，莱美药业发布公告，控股股东中恒集团正在筹划有关公司的股份公开征集转让事宜，该事项可能导致公司的控股股东及实控人发生变更。表决权委托协议正式签署并生效后，中恒集团成为持有莱美药业表决权份额最大的单一股东，莱美药业的实控人变更为广西壮族自治区国资委。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128132717abe4fd9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128132717abe4fd9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0070","BK0012","600252","300006","BK0077","BK0028","BK0239","BK0015"],"gpt_icon":0},{"id":"2486816323","title":"重庆A股58家上涨 莱美药业20%涨幅第一 远达环保10%涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2486816323","media":"上游新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486816323?lang=zh_cn&edition=full","pubTime":"2024-11-28 07:14","pubTimestamp":1732749240,"startTime":"0","endTime":"0","summary":"2024年11月27日，78家重庆A股上市公司中有58家上涨。数据显示，莱美药业以上涨20.00%位居第一，远达环保以上涨10.00%列第二，宗申动力6.97%列涨幅第三。莱美药业20%为涨幅第一莱美药业报收5.82元，当日上涨20.00%（涨停），今年以来上涨56.45%，换手率11.30%。丰华股份报收13.81元，当日下跌6.37%，换手率17.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128071702abe442c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128071702abe442c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600292","300006","BK0028","399300","BK0188","BK0218","BK0160","BK0010","BK0150","BK0070","159982"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-10-30","address":"重庆市南岸区玉马路99号","stockEarnings":[{"period":"1week","weight":-0.1765},{"period":"1month","weight":0.0699},{"period":"3month","weight":0.7563},{"period":"6month","weight":1.0248},{"period":"1year","weight":0.3351},{"period":"ytd","weight":0.3172}],"companyName":"重庆莱美药业股份有限公司","boardCode":"AI0027","perCapita":"37242股","boardName":"医药制造业","registeredCapital":"105591万元","compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1705},{"period":"6month","weight":0.1274},{"period":"1year","weight":0.1497},{"period":"ytd","weight":0.1265}],"survey":" 重庆莱美药业股份有限公司的主要业务为医药制造，公司产品品种丰富，结构合理，公司主要产品为化药，涵盖特色专科类（主要包括抗肿瘤药、消化系统药、肠外营养药）、抗感染类等。公司重点品种纳米炭混悬注射液(卡纳琳)，系首款获得CFDA批准的淋巴示踪剂，卡纳琳连续四年获得“中国化学制药行业原研药,专利药优秀产品品牌”,连续两年获得“中国化学制药行业其他各科用药优秀产品品牌”,获得“制造业单项冠军产品(2019-2021年)”,“2021年中国产学研合作创新与促进奖”等多项荣誉称号。","serverTime":1734984453713,"listedPrice":16.5,"stockholders":"28350人(较上一季度增加1.25%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱美药业,300006,莱美药业股票,莱美药业股票老虎,莱美药业股票老虎国际,莱美药业行情,莱美药业股票行情,莱美药业股价,莱美药业股市,莱美药业股票价格,莱美药业股票交易,莱美药业股票购买,莱美药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱美药业(300006)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱美药业(300006)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}